JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, K. E.
Right arrow Articles by Rech, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, K. E.
Right arrow Articles by Rech, R. H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DOPAMINE
*ETHYL CARBAMATE
*FLUPHENAZINE
*L-TYROSINE
Journal of Pharmacology And Experimental Therapeutics, Vol. 156, Issue 1, 70-75, 1967
Copyright © 1967 by American Society for Pharmacology and Experimental Therapeutics


ANTAGONISM BY MONOAMINE OXIDASE INHIBITORS OF agr-METHYLTYROSINE-INDUCED CATECHOLAMINE DEPLETION AND BEHAVIORAL DEPRESSION

Kenneth E. Moore 1 and Richard H. Rech 1

1 Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire

Multiple intraperitoneal injections of agr-methyl-tyrosine (agrMT, 50 mg/kg/4 hr for three doses) cause a reduction of brain stores of norepinephrine and dopamine and a progressive impairment of conditioned avoidance and Rotarod performance in rats. Rats which have been pretreated with monoamine oxidase inhibitors (JB516 or tranylcypromine, 10 mg/kg) 16 hr prior to the start of the agrMT injections exhibit significantly less loss of avoidance behavior and less brain catecholamine depletion than rats pretreated with saline. Pretreatment with either monoamine oxidase inhibitor also prevents the impaired Rotarod performance induced by agrMT but not that induced by urethane or fluphenazine. Monoamine oxidase inhibitors have no effect upon the brain and plasma contents of agrMT. Thus the behavioral deficit induced by agrMT is more closely related to the reduction of brain catecholamines than to the actual concentration of agrMT in the brain.

Submitted on June 29, 1966
Accepted on October 18, 1966




This article has been cited by other articles:


Home page
ScienceHome page
D. E. Redmond Jr., I. W. Maas, A. Kling, C. W. Graham, and H. Dekirmenjian
Social Behavior of Monkeys Selectively Depleted of Monoamines
Science, October 22, 1971; 174(4007): 428 - 431.
[Abstract] [PDF]


Home page
ScienceHome page
A. Horita and A. E. Hamilton
Lysergic Acid Diethylamide: Dissociation of Its Behavioral and Hyperthermic Actions by DL-agr-Methyl-p-Tyrosine
Science, April 4, 1969; 164(3875): 78 - 79.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1967 by the American Society for Pharmacology and Experimental Therapeutics.